![Organ failure / Immunosuppressants / Eculizumab / Kidney diseases / Hemolytic-uremic syndrome / Chronic kidney disease / Dialysis / Pharmaceutical Benefits Scheme / Kidney transplantation / Medicine / Health / Nephrology Organ failure / Immunosuppressants / Eculizumab / Kidney diseases / Hemolytic-uremic syndrome / Chronic kidney disease / Dialysis / Pharmaceutical Benefits Scheme / Kidney transplantation / Medicine / Health / Nephrology](/pdf-icon.png) Date: 2015-03-12 23:53:04Organ failure Immunosuppressants Eculizumab Kidney diseases Hemolytic-uremic syndrome Chronic kidney disease Dialysis Pharmaceutical Benefits Scheme Kidney transplantation Medicine Health Nephrology | | Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical BenefiAdd to Reading ListSource URL: pbs.gov.auDownload Document from Source Website File Size: 48,27 KBShare Document on Facebook
|